Accelerate Diagnostics (STU:1A80) ROCE % : -278.33% (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Accelerate Diagnostics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Accelerate Diagnostics's annualized ROCE % for the quarter that ended in Mar. 2024 was -278.33%.

Accelerate Diagnostics ROCE % Historical Data

The historical data trend for Accelerate Diagnostics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerate Diagnostics ROCE % Chart

Accelerate Diagnostics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-46.83

-55.77

-79.43

-168.47

-597.64

Accelerate Diagnostics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-	-	-	-394.41	-278.33

Accelerate Diagnostics ROCE % Calculation

Accelerate Diagnostics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-48.624	/	( ( (61.374 - 62.83)	+	(28.763 - 11.035) )	/ 2 )
	=	-48.624	/	( (-1.456	+	17.728)	/ 2 )
	=	-48.624	/	8.136
	=	-597.64 %

Accelerate Diagnostics's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-43.352	/	( ( (28.763 - 11.035)	+	(28.264 - 14.841) )	/ 2 )
	=	-43.352	/	( ( 17.728	+	13.423 )	/ 2 )
	=	-43.352	/	15.5755
	=	-278.33 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Accelerate Diagnostics (STU:1A80) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Accelerate Diagnostics ROCE % Related Terms

Thank you for viewing the detailed overview of Accelerate Diagnostics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Accelerate Diagnostics (STU:1A80) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Accelerate Diagnostics Inc (STU:1A80) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

AXDX:USA AXDX:Mexico 1A80:Germany

Address

3950 South Country Club Road, Suite 470, Tucson, AZ, USA, 85714

Website

https://www.acceleratediagnostics.com

Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.

Accelerate Diagnostics (STU:1A80) Headlines

No Headlines